The Swiss pharma group has agreed a $9 per share deal to acquire Poseida, valuing the company at around $1 billion, with another $500 million potentially payable to shareholders in a contingent value ...

The global CAR-T Cell Therapy market size is expected to reach USD 8.92 billion by 2026 growing at a CAGR of 34.5% from 2020 to 2026 according to a new study published by Report Ocean. Request To ...

Galapagos NV (NASDAQ:GLPG – Get Free Report) has been assigned an average recommendation of “Reduce” from the seven analysts that are presently covering the company, Marketbeat Ratings reports. Two ...

Galapagos (NASDAQ:GLPG – Get Free Report) was downgraded by equities researchers at Kepler Capital Markets from a “hold” rating to a “reduce” rating in a research report issued on Wednesday, ...

If consummated, the deal will add a BCMA and CD19-targeted CAR-T therapy for blood cancers including relapsed and refractory multiple myeloma, for which it is in a phase 1b/2 trial in the US.

KYV-101: Kyverna Therapeutics KYV-101 is an autologous version of a novel, fully human clinical-stage anti-CD19 chimeric antigen receptor T-cell (CAR T) construct with properties well suited for ...

KYV-101: Kyverna Therapeutics KYV-101 is an autologous version of a novel, fully human clinical-stage anti-CD19 chimeric antigen receptor T-cell (CAR T) construct with properties well suited for use ...

CARVICTI has now achieved nearly 90% market share in the BCMA CAR T class of sales in the U. S. And Germany, and it continues to be the fastest launch CAR T product on the market. With the ...

In cases involving unpredictable factors, such as most chemical reactions, pharmaceutical activity, and physiological ...